Clinical Trials Logo

PTEN Positive clinical trials

View clinical trials related to PTEN Positive.

Filter by:
  • None
  • Page 1

NCT ID: NCT03207529 Completed - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Start date: June 7, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of alpelisib when given together with enzalutamide in treating patients with androgen receptor and PTEN positive breast cancer that has spread to other places in the body. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Androgen receptor can cause the growth of breast cancer cells. Hormone therapy using enzalutamide may fight breast cancer by lowering the amount of androgen the body makes. Giving alpelisib and enzalutamide may work better in treating patients with breast cancer.